Literature DB >> 3427825

Dose-response effects in immunizations with keyhole limpet haemocyanin and rabies vaccine: shift in some immunodeficiency states.

K Korver1, E W Boeschoten, R T Krediet, G van Steenis, P T Schellekens.   

Abstract

We investigated the primary antibody response to the antigens keyhole limpet haemocyanin (KLH) and rabies vaccine (RV). Eighty-one healthy volunteers were injected with nine doses of KLH (ranging from 10 to 2500 micrograms) and 66 volunteers with six doses of RV (ranging from 17 to 680 micrograms protein). Anti-KLH and anti-RV antibodies were determined by ELISA and immunofluorescence (IF) immediately before and 14 days after primary immunization. On the basis of the dose-response curves, optimal and supra-optimal antigen doses were chosen for the assessment of humoral immunocompetence in two groups of patients with uraemic disease, who were treated either by chronic intermittent (hospital) haemodialysis (HD) (n = 16), or continuous ambulatory peritoneal dialysis (CAPD) (n = 23). The patients were randomly immunized with 250 micrograms or 2.5 mg KLH and 170 micrograms or 680 micrograms RV and their antibody responses were compared with those obtained in healthy individuals. We found a definite deficiency in the primary response in haemodialysis patients after challenging with a suitable antigen dose. However, the differences in response rate between patients and controls tended to disappear upon stimulation with a supra-optimal antigen dose. This might indicate that the dose-response curve of a particular antigen is shifted towards higher doses of antigen in immunodeficiency states, which could have important consequences for the testing of immunocompromised patients.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3427825      PMCID: PMC1542077     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  19 in total

1.  New approach to the production of concentrated and purified inactivated polio and rabies tissue culture vaccines.

Authors:  A L van Wezel; G van Steenis; C A Hannik; H Cohen
Journal:  Dev Biol Stand       Date:  1978

2.  Primary immunodeficiency diseases. Report of a World Health Organization scientific group.

Authors: 
Journal:  Clin Immunol Immunopathol       Date:  1986-07

3.  A rapid reproducible test for determining rabies neutralizing antibody.

Authors:  J S Smith; P A Yager; G M Baer
Journal:  Bull World Health Organ       Date:  1973-05       Impact factor: 9.408

4.  Defective antigen presentation by macrophages from mice genetically selected for low antibody response.

Authors:  L Adorini; G Doria
Journal:  Eur J Immunol       Date:  1981-12       Impact factor: 5.532

Review 5.  Correlation between genetic regulation of immune responsiveness and host defence against infections and tumours.

Authors:  G Biozzi
Journal:  Eur J Clin Invest       Date:  1982-10       Impact factor: 4.686

6.  Antibody responses after immunization with polyvalent pneumococcal vaccine containing 10, 25, or 50 micrograms of 14 polysaccharide types per dose.

Authors:  F R Cano; M V Querry; C J Tarrant; M B Ritchey; G Schiffman
Journal:  Proc Soc Exp Biol Med       Date:  1983-09

7.  Continuous ambulatory peritoneal dialysis - 1981.

Authors:  D G Oreopoulos; R Khanna; P Williams; S I Vas
Journal:  Nephron       Date:  1982       Impact factor: 2.847

Review 8.  Host defenses and immunologic alterations associated with chronic hemodialysis.

Authors:  S E Goldblum; W P Reed
Journal:  Ann Intern Med       Date:  1980-10       Impact factor: 25.391

9.  Graphical method for evaluating antibody response to vaccines.

Authors:  G R Siber; B J Ransil; G Schiffman
Journal:  Infect Immun       Date:  1980-05       Impact factor: 3.441

10.  The immune response of healthy adults to a reduced dose of hepatitis B vaccine.

Authors:  W Szmuness; C E Stevens; E J Harley; E A Zang; P E Taylor; H J Alter
Journal:  J Med Virol       Date:  1981       Impact factor: 2.327

View more
  4 in total

Review 1.  Rabies virus vaccine as an immune adjuvant against cancers and glioblastoma: new studies may resurrect a neglected potential.

Authors:  M A Altinoz; S Guloksuz; I Elmaci
Journal:  Clin Transl Oncol       Date:  2017-01-16       Impact factor: 3.405

2.  Intraperitoneal immunization of human subjects with tetanus toxoid induces specific antibody-secreting cells in the peritoneal cavity and in the circulation, but fails to elicit a secretory IgA response.

Authors:  C Lue; A W van den Wall Bake; S J Prince; B A Julian; M L Tseng; J Radl; C O Elson; J Mestecky
Journal:  Clin Exp Immunol       Date:  1994-05       Impact factor: 4.330

3.  Vaccination with rabies to study the humoral and cellular immune response to a T-cell dependent neoantigen in man.

Authors:  D M C Brinkman; C M Jol-van der Zijde; M M ten Dam; J M Vossen; A D M E Osterhaus; F P Kroon; M J D van Tol
Journal:  J Clin Immunol       Date:  2003-11       Impact factor: 8.542

4.  Neutralizing Antibody Response after Intramuscular Purified Vero Cell Rabies Vaccination (PVRV) in Iranian Patients with Specific Medical Conditions.

Authors:  Pooneh Rahimi; RouhAllah Vahabpour; Mohammad Reza Aghasadeghi; Syed Mehdi Sadat; Nader Howaizi; Ehsan Mostafavi; Ali Eslamifar; Vida Fallahian
Journal:  PLoS One       Date:  2015-10-06       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.